Buy Hold Sell: 6 ASX small caps thriving in a macro storm
Right now, bond markets are front of mind for investors. In this episode of Buy Hold Sell, we explore what that means for small caps.
Sticky inflation and ballooning budget deficits are pushing yields higher, and with the RBA likely to hike rates again, the question isn't just which stocks look cheap; it's which ones can survive and thrive even as the cost of capital keeps rising.
Small caps are particularly exposed in this environment and get hit harder when sentiment turns. But within this universe, there are always names with the earnings quality, balance sheet strength, or structural tailwinds to hold their ground.
To find which ones can weather the storm, Matthew Nicholas from 1851 Capital and Nick Sladen from LSN Capital Partners run the ruler over four small caps, and each share a high-conviction pick each.
This episode was filmed Wednesday 16th September, 2025.
Other ways to listen
Episode summary
1 - Integral Diagnostics (ASX: IDX)
Nick Sladen - BUY
His verdict: Strong structural tailwinds across MRI deregulation, GP incentives, and an ageing population. A new CEO can drive higher returns by sweating existing assets and potentially selling the New Zealand business to pay down debt.
What he said: "It trades on sub seven times EV to EBITDA. There's a lot of transactions in the private market going on through 10 and 12 times."
His verdict: Cheap stock with a great new CEO, but rising competition as wider MRI deregulation kicks in, potential doctor remuneration friction, and high leverage keep him on the sidelines.
What he said: "They get a bit of a free kick and a lot of their machines get deregulated ahead of the market. The rest of the market now gets deregulated in 12 months from now and we think competition will begin to increase."
2 - Bravura Solutions (ASX: BVS)
His verdict: The market isn't giving management credit for the turnaround. Record-low customer churn, proven pricing power, and deep operational cost cuts set the business up for accelerating top-line growth.
His verdict: Impressive profitability turnaround driven by cost-cutting, but top-line growth looks limited and there are better high-growth opportunities elsewhere.
3 - Zip Co (ASX: ZIP)
His verdict: Phenomenal momentum in the US market, lower funding costs from a recent refinancing package, and non-discretionary product mix make it resilient despite consumer pressure.
His verdict: Management executed a great balance sheet cleanup, but an untested environment with US interest rate hikes, rising bad debt provisions, and sensitivity to domestic interest rates create near-term risk.
4 - COG Financial Services (ASX: COG)
His verdict: Largest portfolio holding. Massively benefits from government policy supporting electric vehicles, driving explosive growth in its salary packaging and novated leasing division.
His verdict: Also his largest position. Lower EV prices expand the customer base, novated leasing is seeing strong organic growth, and a fortress balance sheet leaves plenty of room for acquisitions.
GUEST PICKS
5 - Cogstate (ASX: CGS) - Nick's pick
His verdict: A transformational expansion beyond Alzheimer's into sleep, psychiatric, and rare diseases. Supported by a debt-free balance sheet, active share buybacks, and strong long-term earnings potential.
6 - FDC Consolidated Holdings (ASX: FDC) - Matthew's pick
His verdict: Strong post-COVID tailwinds in office reconfigurations and infrastructure. Driven by a risk-averse management team, wide equity ownership across key staff, and exceptionally high revenue certainty.
5 topics
6 stocks mentioned
2 contributors mentioned